Tricyclic PARP inhibitors

Details for Australian Patent Application No. 2004261462 (hide)

Owner Pfizer, Inc. Cancer Research Technology Limited

Inventors Helleday, Thomas; Curtin, Nicola

Agent Callinan

Pub. Number AU-B-2004261462

PCT Pub. Number WO2005/012305

Priority 0408524.7 16.04.04 GB; 0317466.1 25.07.03 GB

Filing date 23 July 2004

Wipo publication date 10 February 2005

Acceptance publication date 22 April 2010

International Classifications

A61K 31/5517 (2006.01)

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61P 35/00 (2006.01) Antineoplastic agents

C07D 487/06 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

23 February 2006 PCT application entered the National Phase

  PCT publication WO2005/012305 Priority application(s): WO2005/012305

21 February 2008 Assignment before Grant

  Cancer Research Technology Limited The application has been assigned to Cancer Research Technology Limited; Pfizer Inc.

22 April 2010 Application Accepted

  Published as AU-B-2004261462

19 August 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004261467-A sunblind

2004261461-Preparation of metal salts of mediumchain fatty acids